Authors

Strengthen Your Retirement with Charity

Epilepsy Market Grows, Widens in 2018

A series of newly marketed therapies—from cannabidiol to smartwatches—showed where the future of epilepsy care may grow.

Gas pain: A diagnosis in the waves

A 59-year-old Indian man with a medical history significant for orally controlled diabetes presented to the emergency department after experiencing a witnessed seizure.

With Asset Protection, Compliance Is Key

Obesity-related hypertension

To evaluate the interactions between the weight loss drug, sibutramine, and different antihypertensive treatments, we randomly assigned 171 subjects taking 3 antihypertensive treatment regimens to receive sibutramine or placebo. Our study showed for the first time that combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker is more advantageous than a ß blocker/diuretic-based-regimen with regard to supporting the weight-reducing actions and metabolic changes induced by sibutramine.

Read a Pair of Classic Investment Tomes

Looking Beyond Seasonal Triggers: Could Eosinophils Be Driving Your Patients' Severe Asthma?

Eosinophilic asthma is characterized by elevated levels of eosinophils, which are a direct cause of chronic inflammation in severe asthma.

Large-scale clinical epidemiology of stable angina in women and men

We performed a whole-country study using linked health care records in Finland and showed that stable angina as the initial symptomatic manifestation of coronary disease occurs as frequently in women as it does in men. Among easily recognized subgroups, the absolute rates of prognostic outcomes were similarly high in women and men.

The Contributors to Suicide, and the Hurdles in Preventing It

Over time, it has become evident that suicide involves a complex mix of genetics, temperament, circumstances, external support, and access to means.

Chart Your Financial Future with Calls

Incidence of death and MI associated with stopping clopidogrel after ACS

Rates of death and myocardial infarction were assessed for a national sample of acute coronary syndrome patients after stopping clopidogrel. In the first 90 days after stopping treatment, patients experienced a nearly twofold increased risk of adverse events compared with subsequent follow-up intervals for patients treated medically without stents and for patients treated with coronary stents. This suggests a possible clopidogrel rebound effect, but additional studies are needed to support this hypothesis and to identify strategies to reduce early events after clopidogrel cessation.